Emerging biological therapies in systemic lupus erythematosus

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 167-171

  Mount, G R ^a   Gilliland, W R ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; AMG 557; AMGEN 623; ATACICEPT; ATLIZUMAB; B CELL ACTIVATING FACTOR; BELIMUMAB; CD20 ANTIGEN; CD40 LIGAND; CORTICOSTEROID; CPG 52364; ECULIZUMAB; EDRATIDE; EFALIZUMAB; EPRATUZUMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; LJP 1082; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEDI 545; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PRO 155767; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANCA ASSOCIATED VASCULITIS; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD11A; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION; B-CELL ACTIVATING FACTOR; BIOLOGICAL THERAPY; CD40 LIGAND; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37549067742     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100436     Document Type: Review

References (30)

1. Mok, C.C. & Lau, C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56, 481-490 (2003).
2. Looney, R.J., Anolik, J. & Sanz, I. B cells as therapeutic targets for rheumatic disease. Curr. Opin. Rheumatol. 16, 180-185 (2004).
3. Khan, I.U., Tsokos, G.C. & Kammer, G.M. Abnormal B cell signal transduction in systemic lupus erythematosus. Curr. Dir. Autoimmun. 6, 89-104 (2003).
4. Guidance for industry on systemic lupus erythematosus developing drugs for treatment Available at 〈www.fda.gov/ohrms/dockets/98fr/2005d-0106- gdl0001.pdf〉 (2005).
5. Reff, M.E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
6. Anolik, J.H. et al. B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): phase I/II trial of rituximab (Rituxan) in SLE [abstract]. Arthritis Rheum. 44 (Suppl), S387 (2001).
7. Anolik, J.H., Campbell, D., Felgar, R., Rosenblatt, J., Young, F. & Looney, R.J. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of ritixumab in SLE [abstract]. Arthritis Rheum. 46 (Suppl), S717 (2002).
8. Anolik, J.H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580-3590 (2004).
9. Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R. & Isenberg, D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44, 1542-1545 (2005).
10. Smith, K.G., Jones, R.B., Burns, S.M. & Jayne, D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970-2982 (2006).
11. Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S.H., Henriksson, E.W. & van Vollenhoven, R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263-1272 (2007).
12. Sato, S. et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5, 551-562 (1996).
13. Dorner, T., Kaufmann, J., Wegener, W.A., Teoh, N., Goldenberg, D.M. & Burmester, G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006).
14. Jacobi, A.M., Goldenberg, D.M., Hiepe, F.T., Radbruch, A., Burmester, G.R. & Dorner, T. Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann. Rheum. Dis.; e-pub ahead of print (2007).
15. Papp, K.A. & Henninger, E. Evaluation of efalizumab using safe psoriasis control. BMC Dermatol. 6, 8 (2006).
16. Usmani, N. & Goodfield, M. Efalizumab in the treatment of discoid lupus erythematosus. Arch. Dermatol. 143, 873-877 (2007).
17. Clayton, T.H., Ogden, S. & Goodfield, M.D. Treatment of refractory subacute cutaenous lupus erythematosus with efalizumab. J. Am. Acad. Dermatol. 54, 892-895 (2006).
18. Janeway, C.A. Jr. & Bottomly, K. Signals and signs for lymphocyte responses. Cell 76, 275-285 (1994).
19. Boumpas, D.T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003).
20. Kalunian, K.C., Davis, J.C. Jr., Merrill, J.T., Totoritis, M.C. & Wofsy, D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled study. Arthritis. Rheum. 46, 3251-3258 (2002).
21. Davidson, A., Diamond, B., Wofsy, D. & Daikh, D. Block and tackle: CTLA4Ig takes on lupus. Lupus 14, 197-203 (2005).
22. Brunet, J.F. et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328, 267-270 (1987).
23. Krummel, M.R. & Allison, J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
24. Judge, T.A., Tang, A., Spain, L.M., Deans-Gratiot, J., Sayegh, M.H. & Turka, L.A. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156, 2294-2299 (1996).
25. Finck, B.K., Linsley, P.S. & Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227 (1994).
26. Daikh, D.I. & Wofsy, D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-2916 (2001).
27. Aringer, M., Graninger, W.B., Steiner, G. & Smolen, J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50, 3161-3169 (2004).
28. Toubi, E., Kessel, A., Rosner, I., Rozenbaum, M., Paran, D. & Shoenfeld, Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand. J. Immunol. 63, 299-303 (2006).
29. Furie, R. et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients [abstract]. Arthritis Rheum. 48 (Suppl), S377 (2003).
30. Smolen, J.S. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis 66, 143-150 (2007).